4D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD

PUBT · 3d ago
4D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD
  • 4D Molecular Therapeutics reported positive 2-year PRISM Phase 2b results for 4D-150 in wet age-related macular degeneration on July 18, 2026.
  • Data were already presented as a 2-year readout using a May 18, 2026 cutoff.
  • Patients maintained vision outcomes and retinal anatomy control over two years, supporting durability from a single intravitreal dose.
  • Results indicated a sustained reduction in follow-on injection needs versus standard aflibercept dosing, reinforcing the Phase 3 development strategy.
  • Safety remained supportive for the Phase 3 dose, with limited early mild inflammation and no new inflammation signals in longer follow-up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-308409), on July 20, 2026, and is solely responsible for the information contained therein.